TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01566669
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before incision, patients in Group C (n = 120) receive 2 mL of normal saline IV. Thereafter, they receive 2 mL of normal saline IV every 12 h for 48 h. 30 min before the end of surgery, a mixture of 6 mL of ropivacaine 0.25% and 2mg morphine was given epidurally. Epidural patient-controlled analgesia was initiated by using ropivacaine 0.125% (1.25 mg/ml) and morphine 0.005% (0.05 mg/ml) with a basal infusion rate of 2 ml/h, a demand dose of 2 ml, and a 15-min lockout.
Study: NCT03110315
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic suvorexant 10 mg tablet.
Study: NCT03365609
Drug: concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole+Amoxicillin+Clarithromycin+Metronidazole
Study: NCT01396278
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching fluticasone propionate HFA MDI
Study: NCT04470622
Drug: Saline Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline Placebo, once daily (QD) for 14 days.
Study: NCT03519022
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The pharmacodynamic effects of placebo will be determined during maintenance on placebo and duloxetine.
Study: NCT03171610
Drug: Sufentanil group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA device containing sufentanil (3 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml was connected.
Study: NCT03171610
Drug: Fentanyl group
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PCA device containing fentanyl (20 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml was connected.
Study: NCT04368403
Drug: KHK4827
Approvals — FDA: no, EMA: no, PMDA: no
Description: 210 mg every 2 weeks (Q2W), subcutaneous (SC) injection
Study: NCT01461655
Drug: marketed topical NSAID
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily application, 4 weeks
Study: NCT01461655
Drug: vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily application, 4 weeks
Study: NCT01461655
Drug: marketed topical retinoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily application, 4 weeks
Study: NCT03675815
Drug: TDF 300 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg orally once daily for 96 weeks
Study: NCT03675815
Drug: 3TC 300 MG Oral Tablet
Normalized name: 3TC 300 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg orally once daily for 96 weeks. Choice of 3TC or FTC will be determined by clinician
Study: NCT00786019
Drug: Ascorbic Acid (Vitamin C)
Normalized name: Ascorbic acid (vitamin C), plain
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During one exercise study visit, 0.06 grams of Vitamin C per kilogram fat-free mass per 100 milliliters (mL) of normal saline administered; Subjects will receive a bolus of 100mL Vitamin C solution given at 5ml/minute over 20 minutes followed by a drip-infusion given at 1.7ml/minute.
Study: NCT03948737
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00268554
Drug: caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01142089
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two matching tablets) orally twice daily for 3 days (72 hours).
Study: NCT00079144
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02387788
Drug: AKB-9778
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 2a open-label study to assess the efficacy and safety of subcutaneous 15mg AKB-9778 administered twice daily for 84 days in subjects with macular edema due to RVO.
Study: NCT02775227
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04444427
Drug: GLR2007
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally, once daily for 21 days followed by a 7-day treatment holiday.
Study: NCT01994499
Drug: Medical drainage
Normalized name: PLEURX DRAINAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical pleural drainage
Study: NCT01757691
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01066442
Drug: BF2.649 (Pitolisant)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D
Study: NCT03923478
Drug: ABI-M201
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Treatment
Study: NCT03923478
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Treatment
Study: NCT01241552
Drug: SOC
Normalized name: Isocet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SOC) for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metranidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
Study: NCT00727233
Drug: Toxicity, Pharmacokinetics
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00727233
Drug: Pharmacodynamics
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00727233
Drug: Radiographic Evaluation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03699319
Drug: 5-flurouracil
Normalized name: 1beta-D-2'-Deoxyribofuranosyl-5-flurouracil
DrugBank: Floxuridine (DB00322)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered at 400 mg/m2 as bolus followed by a 46-hr infusion at 2400 mg/m2, starting immediately after completion of folinic acid and irinotecan~Part of SOC mFOLFRINOX treatment combination of Oxaliplatin, Irniotecan, 5-flurouracil, and vitamin derivative (Folinic acid)
Study: NCT03579875
Drug: Total Body Irradiation (TBI) (Plan 1)
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 cGy with thymic shielding on day -6
Study: NCT03579875
Drug: Cyclophosphamide (CY) (Plan 1)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg/kg IV daily on days -5, -4, -3, and -2
Study: NCT03579875
Drug: Cyclophosphamide (CY) (Plan 2)
Normalized name: cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg/kg IV daily on days -5, -4, -3, and -2
Study: NCT00528866
Drug: LHRH agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH agonist (such as leuprolide, goserelin, buserelin, or triptorelin) for 6 months, starting within 6 weeks after registration
Study: NCT01881217
Drug: BAY1179470
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY1179470 will be administered as a 1-hour intravenous infusion.
Study: NCT00128518
Drug: Indapamide (T2)
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5 mg/day during 4 weeks
Study: NCT00128518
Drug: Placebo of Indapamide (P2)
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 pill/day during 4 weeks
Study: NCT00306137
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution was supplied in identical vials and will consist of 200mL of 0.9% sodium chloride.
Study: NCT02923115
Drug: DS-1040b
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single, continuous intravenous infusion over 12 to 24 hours (depending on cohort)
Study: NCT02923115
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single, continuous intravenous infusion of 0.9% sodium chloride over 12 to 24 hours
Study: NCT02888665
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03455192
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04401020
Drug: SAR442257
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Sterile powder for reconstitution Route of administration: Intravenous infusion
Study: NCT02701088
Drug: 5Fluorouracile and Mitomycin-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: All the patients will receive radiochemotherapy with two cycles of 5FU (1,000 mg/m²/d with 96-h infusion, days 1-5 and 29-33 of SIB-IMRT) and Mitomycin-C (10 mg/m², days 1 and 29).
Study: NCT00712660
Drug: antipsychotic dose increase
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% increase in the dose of current antipsychotic medication
Study: NCT01221454
Drug: Conserved therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral or intravenous administration
Study: NCT02153476
Drug: 2.0mg of ALG-1001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00101894
Drug: FOLFOX-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: The FOLFOX-4 regimen will be administered every 2 weeks as follows:~Day 1: oxaliplatin (ELOXATIN™) 85 mg/m2 IV infusion and leucovorin racemate 200 mg/m2 (or 100 mg/m2 l-LV) IV infusion given over 120 ± 10 minutes at the same time in separate bags using a Y-line, followed by 5-FU 400 mg/m2 IV bolus given over 2 to 4 minutes, followed by 5-FU 600 mg/m2 IV infusion as a 22-hour ± 2 hours continuous infusion Day 2: leucovorin racemate 200 mg/m2 (or 100 mg/m2 l-LV) IV infusion over 120 ± 10 minutes, followed by 5-FU 400 mg/m2 IV bolus given over 2 to 4 minutes, followed
Study: NCT00101894
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan will be administered over 90 minutes ± 15 minutes on day 1 of each 2-week cycle. Leucovorin will be administered over 2 hours ± 15 minutes during the irinotecan infusion but without mixing, immediately followed by a 5-FU bolus and a 5-FU 46-hour ± 2-hour continuous intravenous infusion.
Study: NCT02410031
Drug: Cyproterone acetate 2mg/ethinylestradiol 35 μg (Diane-35)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate 2mg/ethinylestradiol 35 μg
Study: NCT00549120
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for propranolol tablets
Study: NCT02556931
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days -6 and -5: 14.5 mg/kg IV daily Days 3 and 4: 50 mg/kg IV daily
Study: NCT00022126
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00022126
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00022126
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00022126
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02532140
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00488839
Drug: IPX056 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPX056 Extended Release capsule containing 20 mg baclofen
Study: NCT00488839
Drug: IPX056 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPX056 Extended Release capsule containing 10 mg baclofen
Study: NCT00488839
Drug: IPX056 30 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPX056 Extended Release capsule containing 30 mg baclofen
Study: NCT00488839
Drug: IPX056 35 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPX056 Extended Release capsule containing 35 mg baclofen
Study: NCT00488839
Drug: Placebo IPX056 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule for IPX056 20 mg
Study: NCT00488839
Drug: Placebo IPX056 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule for IPX056 40 mg
Study: NCT00727896
Drug: Diabetes Treatment
Normalized name: Diabetes Ancillary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Life style modification and drug therapy
Study: NCT04130854
Drug: APX005M, mFOLFOX, and Radiation Therapy 5Gy x 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. APX005M 0.3mg/kg intravenously on day 3 of radiation and on day 3 of cycles 1-5 of mFOLFOX~2. Short course radiation therapy 5 Gy x 5 days~3. Oxaliplatin 85mg/m2 intravenous day 1 of each cycle~4. Leucovorin 400mg/m2 IV Day 1 of each cycle~5. 5-FU 2400 mg/m2 continuous infusion over 46 hours of each cycle
Study: NCT04130854
Drug: mFOLFOX and Radiation Therapy 5Gy x 5 days
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Short course radiation therapy 5 Gy x 5 days~2. Oxaliplatin 85mg/m2 intravenous day 1 of each cycle~3. Leucovorin 400mg/m2 IV Day 1 of each cycle~4. 5-FU 2400 mg/m2 continuous infusion over 46 hours of each cycle
Study: NCT00324129
Drug: MGCD0103
Approvals — FDA: no, EMA: no, PMDA: no
Description: MGCD0103 given orally three times per week.
Study: NCT00874770
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral, 0 mg, Daily 48 weeks
Study: NCT03875378
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo weekly patch
Study: NCT03891667
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive disulfiram for 4 weeks followed by placebo for 4 weeks or disulfiram for 8 weeks.
Study: NCT02138617
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200-400 mg/m2 IV over 2 hours, Day 1 and Day 15
Study: NCT02515955
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive minocycline 100 mg as capsule twice daily.
Study: NCT00002967
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002967
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00404456
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin 3 mg once-daily
Study: NCT02169817
Drug: Oral Rehydration Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:vials/sachets for solution Route of administration: oral
Study: NCT03496324
Drug: Nurofen for Children®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurofen for Children® 400 mg/10 ml
Study: NCT04406883
Drug: Extraction + filled with Simvastatin solution impregnated gelatin sponge
Normalized name: succinylated gelatin Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: All two first premolars were extracted carefully, have used periotome as a means of atraumatic extraction that facilitated the removal of teeth with minimum damage to the surrounding alveolar bone, teeth to be extracted should have minimum periapical changes radiographically; with decreasing soft tissue reflection; the socket was tan gently irrigated with normal saline and hemostasis was achieved. It must be noted that A group (Extraction + filled with Simvastatin (Poursina Pharmaceutical Co. Tehran-Iran) solution impregnated gelatin sponge (Maquira Industry Dental Products S.A. Brazil) and B group (Extraction + without Simvastatin solution impregnated gelatin sponge), was placed in one of the sockets.
Study: NCT00092651
Drug: MK0653A, ezetimibe (+) simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01188005
Drug: Vitamin A, Vitamin C, Vitamin E, Allopurinol, N-Acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A 50,000 IU, Vitamin C 1000 mg , Vitamin E 200 mg, Allopurinol 600 mg, N-Acetylcysteine 2 g. Duration is set for 60 days
Study: NCT03496324
Drug: Algifor® Junior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algifor® Junior 400 mg/20 ml
Study: NCT03563144
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine
Study: NCT03563144
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Study: NCT03563144
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
Study: NCT01365676
Drug: GAMALINE® + HIPERICIN®
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAMALINE® 900mg + HIPERICIN 300mg T0 = 2 soft caps of each / day (1st month) T1-T6 = 1 soft caps of each / day (2nd - 6th month)
Study: NCT01365676
Drug: GAMALINE®
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAMALINE® 900mg T0= 2 soft caps / day (1st month) T1-T6 = 1 soft caps / day (2nd - 6th month)
Study: NCT01980082
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01573442
Drug: testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10.4 mg
Study: NCT03649659
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is being compared to the SDF and will also be applied twice
Study: NCT03691090
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03300648
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 3 percent hypertonic saline for a maximum of 7 days
Study: NCT03635814
Drug: YD312 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: YD312 50mg \* 1 + placebo 6 tablets
Study: NCT03635814
Drug: YD312 150mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: YD312 50mg \* 3 + placebo 6 tablets
Study: NCT03635814
Drug: YD312 350mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: YD312 50mg \* 7 tablets
Study: NCT06182631
Drug: Vapocoolent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vapocoolent is a volatile refrigerated liquid, ie ethyl chloride, which is supposed to feel like the skin is numb before insertion of the IV.
Study: NCT04274543
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline solution is a mixture of sodium chloride in water (9 g NaCl per liter water, 0.9% saline). Trephination allows for vascular growth and healing, especially in the inner avascular regions of the meniscus, by puncturing the meniscus. Small tunnels are created, which allow for healing factors to reach the avascular inner region of the meniscus from the vascular peripheral regions.
Study: NCT03635814
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: YD312 0mg \* 7 tabets
Study: NCT02564107
Drug: Ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive ibandronate, 50 milligrams (mg) by mouth every morning, for a period of 25 weeks.
Study: NCT00038584
Drug: SCH66336
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02104310
Drug: Fluorine-18-L-dihydroxyphenylalanine
Normalized name: L-3,4-dihydroxyphenylalanine
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5 millicuries ± 10%; Intravenous injection; 1 time
Study: NCT04077437
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of placebo with therapy during three experimental sessions
Study: NCT01109173
Drug: Nepafenac Ophthalmic Suspension, 0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days. An additional dose was administered between 30-120 minutes prior to surgery.
Study: NCT01109173
Drug: Nepafenac Ophthalmic Suspension, 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye three times daily, for 16 days
Study: NCT00451594
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional dose prednisone (Arm 2)~1. Prednisone, 1 mg/kg is started at diagnosis. If the platelet count is more than 100X109/L, the dose should be used for 4 weeks minimally and then tapered by 10 mg/1 wk until the dose reaches 0.5 mg/kg of body weight and by 5 mg/1 wk thereafter. (Ann Intern Med 1997, 126, 307-14). If the platelet count is between 30X109/L and 100X109/L, prednisone 1 mg/kg should be used for 8 weeks maximally and then tapered by 10 mg/2 wk until the dose reaches 0.5 mg/kg of body weight and by 5 mg/2 wk thereafter.~2. Guideline of prednisone tapering Duration of prednisone treatment: 3-6 months
Study: NCT02760043
Drug: LIA Combination Mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mL 2% Ropivacaine, 30mg Ketorolac and 0.6mg of Epinephrine
Study: NCT04016740
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative infusion
Study: NCT03000127
Drug: AndroGel 1 % Topical Gel
Normalized name: AndroGel 1 % Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: testosterone gel
Study: NCT03000127
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel
Study: NCT04166773
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04072822
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT01409161
Drug: Tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04423029
Drug: DF6002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT01214174
Drug: IBI-10090
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03342300
Drug: pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Several efforts have been made to improve the toxicity profile of conventional anthracyclines, including the use of liposomal encapsulation technology,such as pegylated liposomal doxorubicin.
Study: NCT00000138
Drug: Prednisolone Phosphate
Normalized name: Prednisolone phosphate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02252536
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet, white to off-white, oval shaped tablets, taken 2 times per day
Study: NCT00789750
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets appearing to be colesevelam